Brain, nerve and cognitive care
Neurology and neuroscience briefs covering diagnosis, disease-modifying therapy and long-term management.
Neurology
The FDA approved apitegromab for patients aged 2 years or older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Rayan Salih · September 23, 2026 · 7 min
Neurology
Pooled evidence found no significant difference in functional independence or symptomatic intracerebral hemorrhage when CT perfusion and noncontrast CT were used to select patients for acute ischemic stroke treatment.
Dr. Abu Bakar · 6 min read
Neurology
A multicenter phase 3 trial supports intravenous fosphenytoin for rapid relief during severe trigeminal neuralgia attacks. Its monitored administration and off-label US status limit where it can be used.
Dr. Abu Bakar · 6 min read
Neurology
Small studies report improvements in fatigue, cognition, sleep and pain among people with long COVID, but a systematic review rates the evidence as low certainty.
Dr. Abu Bakar · 6 min read
Neurology
Staged bilateral focused ultrasound produced only small additional motor gains in Parkinson’s disease while leaving more patients with persistent moderate or severe adverse events.
Rayan Salih · 6 min read
Neurology
The cited 2026 WHO media-briefing record does not provide enough verifiable detail to identify revised dementia recommendations. Established guidance still supports integrating cardiovascular and behavioral risk reduction into routine care.
Rayan Salih · 6 min read
Neurology
Selected patients with salvageable brain tissue may benefit from IV thrombolysis 4.5 to 24 hours after ischemic stroke onset, although symptomatic intracranial hemorrhage risk is higher.
Dr. Abu Bakar · 6 min read
Neurology
Recurrent ischemic stroke is one of the most devastating yet preventable medical problem.
Dr. Abu Bakar · 6 min read
Neurology
The use of retinal markers for the early detection of biological changes in Alzheimer’s disease is becoming increasingly
Rayan Salih · 9 min read
Neurology
For generations of pediatricians, neonatologists, and pediatric neurologists, a diagnosis of Spinal Muscular Atrophy (SMA) Type 1 carried
Rayan Salih · 8 min read
Neurology
Schizophrenia has long been recognized as one of the most complex, chronic, and debilitating challenges in modern psychiatry….
Rayan Salih · 11 min read
Neurology
For patients with uncontrolled epilepsy, the threat of an unexpected seizure is a constant source of profound anxiety….
Rayan Salih · 9 min read
Neurology
For decades, the clinical narrative surrounding migraine and stroke risk has been clear-cut, specific, and highly selective.
Rayan Salih · 8 min read
Neurology
The landscape of neuroinfectious diseases is shifting beneath our feet.
Rayan Salih · 8 min read
Neurology
Huntington’s Disease (HD) represents one of the most challenging neurodegenerative conditions in modern medicine.
Rayan Salih · 8 min read
Neurology
Motif Neurotech has won FDA permission to start clinical testing of a tiny brain implant for treatment-resistant depression….
Dr. Abu Bakar · 6 min read
Neurology
No longer are decades of misdiagnosis of Alzheimer’s disease acceptable.
Rayan Salih · 12 min read
Neurology
The Fetal Alcohol Spectrum Disorder (FASD) is a lifelong brain disorder that results from alcohol consumption by pregnant
Dr. Abu Bakar · 7 min read
Neurology
Narcolepsy is a chronic neurological sleep disorder that rarely exists alone.
Dr. Abu Bakar · 6 min read
Neurology
As in previous years the Annual Meeting of the American Academy of Neurology (AAN) was a large convention
Rayan Salih · 13 min read
Neurology
A Summary of the 2026 AAN Annual Meeting for Rare Diseases from a Managed Care Perspective – Myasthenia
Rayan Salih · 9 min read
Neurology
ADHERE post hoc data at AAN 2026 show 87.5% of treatment-naive CIDP patients respond early to Vyvgart Hytrulo, challenging IVIG step therapy.
Rayan Salih · 7 min read
Neurology
ADAPT Jr data show 80% of adolescent gMG patients achieved minimal symptom expression by cycle two with efgartigimod at AAN 2026.
Rayan Salih · 7 min read
Neurology
Research to treat Alzheimer’s and other neurodegenerative diseases has been largely focused on removal of amyloid-beta plaques and
Rayan Salih · 10 min read
Neurology
Phase 3 ADAPT OCULUS data at AAN 2026 show efgartigimod significantly improves ocular MG symptoms, supporting a planned FDA sBLA submission for the oMG indication.
Rayan Salih · 2 min read
Neurology
Phase 3 ADAPT SERON data at AAN 2026 show efgartigimod significantly improves MG-ADL scores in seronegative gMG patients, with FDA priority review targeting May 10, 2026.
Rayan Salih · 8 min read
Neurology
An early trial of the method involving lithium treatment in people with mild cognitive impairment (MCI) revealed that
Dr. Abu Bakar · 7 min read
Neurology
The U.S. Food and Drug Administration today approved Avlayah (tividenofusp alfa-eknm) for the management of central neurologic manifestations
Rayan Salih · 10 min read
Neurology
CAR-T cells that have been redirected to B cell maturation antigen (BCMA) may also be useful for treating
Rayan Salih · 3 min read
Neurology
The MIND diet may help ward off dementia, and a new study finds it may even slow down
Rayan Salih · 11 min read
Neurology
Acetylcholine receptor-positive myasthenia gravis (AChR-positive MG) is an autoimmune disease that leads to Fatigable weakness, often fluctuating in
Dr. Abu Bakar · 13 min read
Neurology
Health care clinicians continue to feel significant levels of burnout.
Rayan Salih · 9 min read
Neurology
Psychosocial problems (depression, anxiety, apathy, isolation, etc.) have become major disabling problems for people with early Parkinson’s disease….
Rayan Salih · 1 min read
Neurology
For decades, Multiple Sclerosis (MS) research focused heavily on relapsing forms of the disease, leaving patients with progressive
Rayan Salih · 7 min read
Neurology
Anti-amyloid therapies, specifically monoclonal antibodies like lecanemab and donanemab, represent a historic shift in Alzheimer’s disease (AD) care,
Rayan Salih · 8 min read
Neurology
While Alzheimer’s disease has a long clinical history, understanding of the disease now extends to the biological changes
Dr. Abu Bakar · 14 min read
Neurology
Fremanezumab is a human monoclonal antibody directed against calcitonin gene-related peptide (CGRP).
Dr. Abu Bakar · 15 min read
Neurology
There is growing interest in the potential of blood-based biomarkers for Alzheimer’s disease to challenge current clinicians’ concepts
Rayan Salih · 9 min read
Neurology
Amyloid, specifically amyloid beta, is the most well-known biological feature of Alzheimer’s disease.
Dr. Abu Bakar · 11 min read
Neurology
More emphasis has been put on alternatives to medication, and some exercises may lower the risk of suffering
Rayan Salih · 1 min read
One story a day
One health journey each morning — no advice, no alarm, just company for the road.
